(BOW) Bowhead Specialty Holdings - Overview
Stock: Casualty, Professional Liability, Healthcare, Excess & Surplus
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 34.2% |
| Relative Tail Risk | 0.64% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.77 |
| Alpha | -33.66 |
| Character TTM | |
|---|---|
| Beta | 0.381 |
| Beta Downside | 0.341 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.56% |
| CAGR/Max DD | 0.07 |
Description: BOW Bowhead Specialty Holdings January 18, 2026
Bowhead Specialty Holdings Inc. (NYSE:BOW) underwrites commercial specialty property-and-casualty insurance across a broad U.S. market, covering construction, distribution, heavy manufacturing, real-estate, hospitality, professional liability (including D&O, E&O, employment practices, fiduciary and fidelity), crime, cyber for financial institutions, and health-care providers. Its Baleen Specialty unit leverages technology-driven underwriting to serve small- and mid-size risks that are typically excluded from the admitted market, and the firm distributes policies through both wholesale and retail partners.
Key recent metrics show Bowhead generated roughly $147 million in net written premiums for 2023, with a combined ratio of 94% and an expense ratio near 30%, indicating disciplined underwriting and cost control. The company’s surplus stood at about $300 million, providing a solid capital cushion in a hardening P&C market where rising construction activity and escalating cyber-risk exposures are driving premium growth. Additionally, a 2024 earnings call highlighted that investment income contributed ~12% of total earnings, underscoring the importance of the current high-interest-rate environment for insurers’ bottom lines.
For a deeper quantitative assessment, you may want to explore Bowhead’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 52.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -3.11 > 1.0 |
| NWC/Revenue: 269.7% < 20% (prev 266.8%; Δ 2.87% < -1%) |
| CFO/TA 0.16 > 3% & CFO 332.9m > Net Income 52.5m |
| Net Debt (-250.8m) to EBITDA (71.1m): -3.53 < 3 |
| Current Ratio: 10.3k > 1.5 & < 3 |
| Outstanding Shares: last quarter (33.7m) vs 12m ago 1.16% < -2% |
| Gross Margin: 33.29% > 18% (prev 0.32%; Δ 3296 % > 0.5%) |
| Asset Turnover: 28.51% > 50% (prev 25.14%; Δ 3.37% > 0%) |
| Interest Coverage Ratio: 67.54 > 6 (EBITDA TTM 71.1m / Interest Expense TTM 1.02m) |
Altman Z'' 4.87
| A: 0.67 (Total Current Assets 1.40b - Total Current Liabilities 136.0k) / Total Assets 2.09b |
| B: 0.05 (Retained Earnings 101.9m / Total Assets 2.09b) |
| C: 0.04 (EBIT TTM 68.8m / Avg Total Assets 1.82b) |
| D: 0.06 (Book Value of Equity 106.9m / Total Liabilities 1.66b) |
| Altman-Z'' Score: 4.87 = AA |
Beneish M -2.78
| DSRI: 1.18 (Receivables 427.0m/272.0m, Revenue 519.2m/389.1m) |
| GMI: 0.97 (GM 33.29% / 32.45%) |
| AQI: 1.04 (AQ_t 0.33 / AQ_t-1 0.31) |
| SGI: 1.33 (Revenue 519.2m / 389.1m) |
| TATA: -0.13 (NI 52.5m - CFO 332.9m) / TA 2.09b) |
| Beneish M-Score: -2.78 (Cap -4..+1) = A |
What is the price of BOW shares?
Over the past week, the price has changed by +1.95%, over one month by -3.25%, over three months by -0.12% and over the past year by -25.90%.
Is BOW a buy, sell or hold?
- StrongBuy: 0
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BOW price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 34.3 | 36.9% |
| Analysts Target Price | 34.3 | 36.9% |
| ValueRay Target Price | 23.9 | -4.4% |
BOW Fundamental Data Overview February 03, 2026
P/E Forward = 15.015
P/S = 1.6452
P/B = 1.8733
Revenue TTM = 519.2m USD
EBIT TTM = 68.8m USD
EBITDA TTM = 71.1m USD
Long Term Debt = unknown (none)
Short Term Debt = 1.50m USD (from shortTermDebt, last fiscal year)
Debt = 4.30m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -250.8m USD (from netDebt column, last quarter)
Enterprise Value = 660.7m USD (854.2m + Debt 4.30m - CCE 197.9m)
Interest Coverage Ratio = 67.54 (Ebit TTM 68.8m / Interest Expense TTM 1.02m)
EV/FCF = 2.01x (Enterprise Value 660.7m / FCF TTM 328.3m)
FCF Yield = 49.69% (FCF TTM 328.3m / Enterprise Value 660.7m)
FCF Margin = 63.23% (FCF TTM 328.3m / Revenue TTM 519.2m)
Net Margin = 10.12% (Net Income TTM 52.5m / Revenue TTM 519.2m)
Gross Margin = 33.29% ((Revenue TTM 519.2m - Cost of Revenue TTM 346.3m) / Revenue TTM)
Gross Margin QoQ = 32.51% (prev 32.47%)
Tobins Q-Ratio = 0.32 (Enterprise Value 660.7m / Total Assets 2.09b)
Interest Expense / Debt = 6.09% (Interest Expense 262.0k / Debt 4.30m)
Taxrate = 20.57% (3.93m / 19.1m)
NOPAT = 54.6m (EBIT 68.8m * (1 - 20.57%))
Current Ratio = 10.3k (out of range, set to none) (Total Current Assets 1.40b / Total Current Liabilities 136.0k)
Debt / Equity = 0.01 (Debt 4.30m / totalStockholderEquity, last quarter 430.2m)
Debt / EBITDA = -3.53 (Net Debt -250.8m / EBITDA 71.1m)
Debt / FCF = -0.76 (Net Debt -250.8m / FCF TTM 328.3m)
Total Stockholder Equity = 399.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.89% (Net Income 52.5m / Total Assets 2.09b)
RoE = 13.14% (Net Income TTM 52.5m / Total Stockholder Equity 399.8m)
RoCE = 3.28% (EBIT 68.8m / Capital Employed (Total Assets 2.09b - Current Liab 136.0k))
RoIC = 13.65% (NOPAT 54.6m / Invested Capital 400.2m)
WACC = 7.31% (E(854.2m)/V(858.5m) * Re(7.32%) + D(4.30m)/V(858.5m) * Rd(6.09%) * (1-Tc(0.21)))
Discount Rate = 7.32% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 3.31%
[DCF Debug] Terminal Value 83.51% ; FCFF base≈313.3m ; Y1≈385.4m ; Y5≈652.2m
Fair Price DCF = 398.5 (EV 12.81b - Net Debt -250.8m = Equity 13.06b / Shares 32.8m; r=7.31% [WACC]; 5y FCF grow 24.63% → 2.90% )
EPS Correlation: 81.39 | EPS CAGR: 59.97% | SUE: 2.63 | # QB: 1
Revenue Correlation: 98.51 | Revenue CAGR: 42.78% | SUE: 0.12 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.42 | Chg30d=-0.002 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=1.96 | Chg30d=-0.065 | Revisions Net=-4 | Growth EPS=+20.3% | Growth Revenue=+21.1%